Killestein J - Search Results

1

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Rispens T, et al. Among authors: killestein j. Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7. Anal Biochem. 2011. PMID: 21216215

2

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.

Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Labrijn AF, et al. Among authors: killestein j. Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20. Nat Biotechnol. 2009. PMID: 19620983

3

T lymphocytes impair P-glycoprotein function during neuroinflammation.

Kooij G, van Horssen J, de Lange EC, Reijerkerk A, van der Pol SM, van Het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE. Kooij G, et al. Among authors: killestein j. J Autoimmun. 2010 Jun;34(4):416-25. doi: 10.1016/j.jaut.2009.10.006. Epub 2009 Dec 2. J Autoimmun. 2010. PMID: 19959334

4

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Killestein J, et al. Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074. Ann Neurol. 2010. PMID: 20661928

5

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.

van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, Oudejans CB, Polman CH, Killestein J. van der Voort LF, et al. Among authors: killestein j. Neurology. 2010 Oct 5;75(14):1228-33. doi: 10.1212/WNL.0b013e3181f6c556. Neurology. 2010. PMID: 20921509

6

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.

Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH. Vennegoor A, et al. Among authors: killestein j. Neurology. 2011 Feb 8;76(6):574-6. doi: 10.1212/WNL.0b013e31820b7644. Neurology. 2011. PMID: 21300973 No abstract available.

7

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Hart MH, et al. Among authors: killestein j. J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29. J Immunol Methods. 2011. PMID: 21824477

8

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.

Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Ketelslegers IA, et al. Among authors: killestein j. Mult Scler. 2011 Dec;17(12):1527-30. doi: 10.1177/1352458511412995. Epub 2011 Aug 9. Mult Scler. 2011. PMID: 21828202

9

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Rispens T, et al. Among authors: killestein j. Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183929

10

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Vennegoor A, et al. Among authors: killestein j. Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19. Mult Scler. 2013. PMID: 22992450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

309 results

Search Page